摘要
目的 探究奥氮平联合氨磺必利治疗精神分裂症的临床效果。方法 方便选取2018年1月-2021年7月厦门市仙岳医院收治的92例精神分裂症患者,将采用氨磺必利治疗的46例患者纳入对照组,采用奥氮平+氨磺必利治疗的46例患者纳入观察组,两组均持续治疗3个月。比较两组治疗前、治疗3个月时病情严重程度、认知功能、焦虑程度、γ-氨基丁酸(GABA)及5-羟色胺(5-HT)水平;比较两组治疗期间不良反应发生率。结果 治疗3个月,观察组阴性症状(14.79±1.63)分、阳性症状(14.33±1.39)分、一般精神病理症状评分(31.88±2.66)分、SAS评分(34.27±2.62)分均低于对照组的(18.11±1.72)分、(18.27±1.58)分、(35.07±3.14)分、(39.51±2.81)分;MoCA评分(25.06±1.64)分、GABA(10.12±0.95)μmol/L、5-HT水平(116.19±11.03)nmol/L均高于对照组的(23.28±1.53)分、(9.29±0.91)μmol/L、(106.79±10.67)nmol/L,差异有统计学意义(t=9.502、12.698、5.257、9.250、5.383、4.279、4.154,P<0.05);两组不良反应发生率比较(10.87%vs 6.52%),差异无统计学意义(P>0.05)。结论 奥氮平与氨磺必利联合作用于精神分裂症患者中,可改善患者临床症状、焦虑程度,提高认知功能,改善神经递质水平,且不会明显增加不良反应。
Objective To explore the clinical effect of olanzapine combined with amsulpiride in the treatment of schizophrenia.Methods A total of ninety-two patients with schizophrenia admitted to the Xiamen Xianyue hospital from January 2018 to July 2021 were conveniently selected,forty-six patients treated with amsulpiride were included in the control group,and forty-six patients treated with olanzapine+amsulpiride were included in the observation group.two groups were treated for 3 months.Before treatment and 3 months after treatment,the severity of illness,cognitive function,anxiety,GABA and 5-HT levels of the two groups were compared.The incidence of adverse reactions during treatment was compared between the two groups.Results After 3 months of treatment,the negative symptom score(14.79±1.63)points,positive symptom score(14.33±1.39)points,general psychopathological symptom score(31.88±2.66)points,SAS score(34.27±2.62)points in the observation group were lower than those in the control group(18.11±1.72)points,(18.27±1.58)points,(35.07±3.14)points and(39.51±2.81)points,MoCA score(25.06±1.64)points,GABA(10.12±0.95)μmol/L,5-HT level(116.19±11.03)nmol/L were higher than those of control group(23.28±1.53)points,(9.29±0.91)μmol/L,(106.79±10.67)nmol/L,and the difference was statistically significant(t=9.502,12.698,5.257,9.250,5.383,4.279,4.154,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(10.87%vs 6.52%)(P>0.05).Conclusion Combined action of olanzapine and amsulpiride in patients with schizophrenia can improve clinical symptoms,anxiety,cognitive function and neurotransmitter levels without significantly increasing adverse reactions.
作者
吴琳
李雪芳
林小荣
WU Lin;LI Xuefang;LIN Xiaorong(Department of Psychiatry,Xiamen Xianyue Hospital,Xiamen,Fujian Province,361000 China)
出处
《中外医疗》
2022年第33期101-104,122,共5页
China & Foreign Medical Treatment
关键词
精神分裂症
氨磺必利
奥氮平
病情程度
焦虑
认知功能
神经递质
Schizophrenia
Amsulpiride
Olanzapine
Degree of illness
Anxiety
Cognitive function
Neurotransmitter
